Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Phase IIa Clinical Study to Evaluate the Safety and Pharmacokinetics of Intravenous and Oral F901318 (Combined With Caspofungin) for Antifungal Prophylaxis in Patients Undergoing Chemotherapy for Acute Myeloid Leukaemia

Next Previous
X
Search
Trial Profile

An Open Label Phase IIa Clinical Study to Evaluate the Safety and Pharmacokinetics of Intravenous and Oral F901318 (Combined With Caspofungin) for Antifungal Prophylaxis in Patients Undergoing Chemotherapy for Acute Myeloid Leukaemia

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 07 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Caspofungin (Primary) ; Olorofim (Primary) ; Olorofim (Primary)
  • Indications Aspergillosis
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms SAFEGUARD
  • Sponsors F2G

    • Most Recent Events

    • 13 Feb 2018 Planned primary completion date changed from 1 Mar 2017 to 21 Apr 2017.
    • 13 Feb 2018 Planned initiation date changed from 1 Sep 2016 to 20 Apr 2017.
    • 13 Feb 2018 Planned End Date changed from 1 May 2017 to 22 Apr 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top